- Jazz Pharmaceuticals (NASDAQ:JAZZ) announced the Health Canada approval and commercial availability of Sunosi (solriamfetol) for adults with excessive daytime sleepiness (EDS) linked to narcolepsy or obstructive sleep apnea (OSA).
- The approval was based on data from the Treatment of Obstructive Sleep Apnea and Narcolepsy Excessive Sleepiness (TONES) Phase 3 clinical program, which included four randomized placebo-controlled studies involving more than 1,500 adults.
- Resulted from conditions such as narcolepsy, EDS is characterized by the inability to stay awake and alert during the day.
- "Jazz is proud to introduce this new therapeutic option to the Canadian market as we continue innovating to transform the lives of patients and their families," noted Paul Petrelli, general manager, Jazz Pharmaceuticals Canada.
In the first half of 2021, the sales of Sunosi for Jazz Pharmaceuticals (JAZZ) more than doubled to reach $23.7M
Jazz Pharma wins Health Canada approval for Sunosi targeting sleeping disorder
Recommended For You
More Trending News
About JAZZ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
JAZZ | - | - |
Jazz Pharmaceuticals plc |